NCT06014944View on ClinicalTrials.gov

Short-course Radiotherapy Combined With Furoquintinib and PD-1 Monoclonal Antibody

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2029

Conditions
Rectal Cancer
Interventions
DRUG

Short-course radiotherapy combined with furoquintinib and PD-1 monoclonal antibody

neoadjuvant therapy for short-course radiotherapy combined with furoquintinib and PD-1 monoclonal antibody for PMMR / MSS type middle and low locally advanced rectal cancer.

All Listed Sponsors
lead

Changhai Hospital

OTHER